Last Price$2.79Cboe Closing Price as of 4:00PM ET 12/05/22
Cboe Real-Time Quotes
Today's Change-0.19(6.23%)
Bid (Size)$2.24 (100)
Ask (Size)$3.25 (100)
Day Low / High$2.67 - 2.95
Volume3.8 M
  • Latest Stories
  • Commentary and Analysis
Agenus Reports 'Strong Durability' of Combination Drug Candidate Against Sarcoma Based on Expanded Phase 1 Data
12:42PM ET 11/17/2022 MT Newswires

Agenus (AGEN) on Thursday reported that expanded data from a phase 1 study of botensilimab and balstilimab in patients with advanced sarcoma showed that...

Agenus Shares Expanded Data From Phase 1 Trial of Botensilimab in Different Cancer Types; Stock Rises
1:29PM ET 11/14/2022 MT Newswires

Agenus (AGEN) said Monday that expanded data from a phase 1 trial showed the potential of botensilimab and balstilimab to treat a range of...

Agenus Swings to Q3 Loss, Revenue Drops; Shares Fall
10:06AM ET 11/08/2022 MT Newswires

Agenus (AGEN) reported Tuesday a Q3 loss of $0.19 per share, compared with earnings of $0.72 per share a year earlier. Four analysts polled by Capital IQ...

VBI Vaccines, Agenus to Collaborate on Phase 2 Trial of Brain Cancer Combination Therapy Candidate
10:19AM ET 10/12/2022 MT Newswires

VBI Vaccines (VBIV) and Agenus (AGEN) said Wednesday they are collaborating on a phase 2 trial of a potential combination therapy for primary glioblastoma,...

--SMBC Nikko Starts Agenus at Outperform With $5 Price Target
7:53AM ET 9/28/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Agenus Starts Phase 2 Trials of Botensilimab for Colorectal Cancer, Advanced Melanoma
10:45AM ET 9/12/2022 MT Newswires

Agenus (AGEN) said Monday it has started separate phase 2 trials, the Activate-Colorectal and the Activate-Melanoma, evaluating botensilimab as a potential...

Agenus Unveils Plan to Double Authorized Common Stock to 800 Million
4:29PM ET 8/05/2022 MT Newswires

Agenus (AGEN) said it filed a certificate of amendment in Delaware to increase the number of authorized common shares to 800 million from 400 million,...

Agenus Doses First Patient in Early Trial of AGEN1571 to Treat Solid Tumors
11:00AM ET 8/01/2022 MT Newswires

Agenus (AGEN) said Monday it has dosed the first patient in the phase 1 study of AGEN1571 to treat advanced solid tumors. The trial will assess the...

Agenus Microsatellite Stable Colorectal Cancer Trial Shows Efficacy -- Stock Gains Wednesday
1:41PM ET 6/29/2022 MT Newswires

Agenus (AGEN) said Wednesday that data from the phase 1b study of botensilimab and balstilimab showed strong efficacy in patients with microsatellite...

Agenus Enters Clinical Collaborations for Tumor Treatments; Shares Rise
10:55AM ET 5/31/2022 MT Newswires

Agenus (AGEN) said Tuesday it has entered into three clinical collaborations with Targovax, Oxford BioTherapeutics and Immunogenesis to develop treatments...